Swedish Orphan Biovitrum
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Swedish Orphan Biovitrum sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Swedish Orphan Biovitrum: 23 sponsored US clinical trials, 2 recruiting.
Swedish Orphan Biovitrum sponsors 23 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 18 completed. 8 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Gout, with 1 trials.
Top-decile sponsor footprint
Swedish Orphan Biovitrum ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734
Assessment of Macrophage Activation syndromE in STill's Disease
NCT06405152
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
NCT05096403
A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation
NCT05148299
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
NCT05001737
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
NCT04596540
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
NCT04513366
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
NCT03985423
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
NCT04324021
Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
NCT03312751
A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients
NCT03811028
A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients
NCT03423186
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
NCT03311854
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
NCT03265132
Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
NCT03103542
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
NCT06047210
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis
NCT03002974
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
NCT03259230
A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody
NCT02069899
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
NCT01818492
Study to Characterize the Effect of Heparin on Palifermin Activity
NCT01163097
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
NCT00460421
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 1 |
What is open in the Swedish Orphan Biovitrum pipeline
2 recruiting of 23 indexed (9% open); 18 completed (78%).
Phase mix: 8 late (III/IV) vs 12 early (I/II) (balanced across stages).
Top condition: Chronic Gout (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Swedish Orphan Biovitrum: open-pipeline peers nationwide
Peers matched on 23 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Swedish Orphan Biovitrum sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Iowa State University · 9% recruiting · 23 trials
- New Approaches to Neuroblastoma Therapy Consortium · 9% recruiting · 23 trials
- Rhythm Pharmaceuticals · 9% recruiting · 23 trials
- University of Nevada, Reno · 9% recruiting · 23 trials
Related
What to do with this Swedish Orphan Biovitrum page
23 registered trials is a research-attention snapshot, not an endorsement of Swedish Orphan Biovitrum or any single study.
- 2 of Swedish Orphan Biovitrum's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Chronic Gout is the condition Swedish Orphan Biovitrum studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Gout trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Swedish Orphan Biovitrum pipeline card: 23 registered trials from official public datasets.Report a data error.